Institutions / Great Point Partners, LLC
Great Point Partners, LLC
CIK 1281446 · Institution · as of Mar 31, 2026
Portfolio value
$408.27M
Positions
39
As of
Mar 31, 2026
Portfolio trend
Portfolio value
$408.27M+32.4%Positions
39+34.5%Top holdings
Mar 31, 2026View all 39 →
| Company | Value | % of portfolio |
|---|---|---|
| Apogee Therapeutics, Inc. | $31.48M | 7.7% |
| Vor Biopharma Inc. | $31.22M | 7.6% |
| Zura Bio Limited | $25.08M | 6.1% |
| Amylyx Pharmaceuticals, Inc. | $24.32M | 6.0% |
| Nektar Therapeutics | $22.77M | 5.6% |
| Sol-Gel Technologies Ltd | $21.74M | 5.3% |
| Alumis Inc.ALMS | $18.86M | 4.6% |
| Bright Minds Biosciences Inc. | $16.05M | 3.9% |
| Annexon, Inc. | $13.85M | 3.4% |
| KalVista Pharmaceuticals Inc | $13.59M | 3.3% |
| Immunovant, Inc.IMVT | $13.55M | 3.3% |
| Jade Biosciences, Inc. | $13.55M | 3.3% |
| Contineum Therapeutics, Inc. | $10.45M | 2.6% |
| Zenas BioPharma, Inc.ZBIO | $10.25M | 2.5% |
| Neurogene Inc.NGNE | $10.08M | 2.5% |
| MoonLake ImmunotherapeuticsMLTX | $9.32M | 2.3% |
| Climb Bio, Inc.CLYM | $9.14M | 2.2% |
| Oruka Therapeutics, Inc. | $8.99M | 2.2% |
| Eupraxia Pharmaceuticals Inc. | $8.69M | 2.1% |
| Vera Therapeutics, Inc. | $8.02M | 2.0% |
| Evommune, Inc.EVMN | $7.47M | 1.8% |
| Lb Pharmaceuticals IncLBRX | $7.40M | 1.8% |
| Compass Therapeutics, Inc. | $7.14M | 1.7% |
| SCYNEXIS, Inc. | $6.93M | 1.7% |
| Palisade Bio, Inc. | $5.96M | 1.5% |
Activity
Mar 31, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | New | Sol-Gel Technologies Ltd | $21.74M | +274K | 274,363 5.32% of portfolio | medium |
| Q1 2026 as of | Exit | IRON Disc Medicine, Inc. Common Stock | $-19.85M | -250K -100.00% | — | medium |
| Q1 2026 as of | Exit | 75382E208 | $-19.68M | -581K -100.00% | — | medium |
| Q1 2026 as of | New | ALMS Alumis Inc. Common Stock | $18.86M | +856K | 856,061 4.62% of portfolio | medium |
| Q1 2026 as of | Exit | Soleno Therapeutics, Inc. | $-18.52M | -400K -100.00% | — | medium |
| Q1 2026 as of | New | Bright Minds Biosciences Inc. | $16.05M | +220K | 220,000 3.93% of portfolio | medium |
| Q1 2026 as of | Exit | Dianthus Therapeutics, Inc. | $-14.42M | -350K -100.00% | — | medium |
| Q1 2026 as of | New | Annexon, Inc. | $13.85M | +2.5M | 2,500,000 3.39% of portfolio | medium |
| Q1 2026 as of | New | ZBIO Zenas BioPharma, Inc. Common Stock | $10.25M | +524K | 524,066 2.51% of portfolio | medium |
| Q1 2026 as of | New | MLTX MoonLake Immunotherapeutics Common Stock | $9.32M | +500K | 500,000 2.28% of portfolio | medium |